Winrho SDF Related Published Studies
Well-designed clinical trials related to Winrho SDF (Rho D Immune Globulin)
Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. [2002.03]
Well-designed clinical trials possibly related to Winrho SDF (Rho D Immune Globulin)
Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura. [2008.12]
A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children. [2008.08]
Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin. [2008.07]
Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. [2006.04]
Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. [2006]
Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. [2004.12.01]
Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. [2003.01]
A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. [2001.03]
Treatment options for chronic idiopathic (immune) thrombocytopenic purpura. [2000.01]
Multicentre trial of antepartum low-dose anti-D immunoglobulin. [1995.03]
The use of anti-D to improve post-transfusion platelet response: a randomized trial. [1995.01]
Other research related to Winrho SDF (Rho D Immune Globulin)
Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment. [2008.04]
Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura. [2007.08]
A prospective study of thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders. [2007.05]
Non-evidence-based use of Rho(D) immune globulin for threatened abortion by family practice and obstetric faculty physicians. [2002.11]
Successful prevention of post-transfusion Rh alloimmunization by intravenous Rho (D) immune globulin (WinRho SD). [1999.03]
Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children. [1998.01]
Safety profile of WinRho anti-D. [1998.01]
[Immunoglobulin G monoclonal human anti-rhesus Rho(D) to prevent rhesus-incompatibility] [1997]
Survival of human monoclonal anti-Rho (D) antibodies in the rhesus monkey. [1992.08]
The treatment of chronic idiopathic thrombocytopenia with anti-D (Rho) immunoglobulin: its effectiveness, safety and mechanism of action. [1988]
Other possibly related research studies
Rapid irreversible encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura. [2004.11]
Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy? [2001.05]
Anti-D: mechanisms of action. [1998.01]
The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. [2006.01]
The issue of anti-D: an integrated seamless approach from recognition of need to bedside administration. [2005.07]
Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin*. [2005.11]
[Evaluation of fetomaternal hemorrhage in postpartum patients with indication for administration of anti-D immunoglobulin] [2005.09]
Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK. [2005.10]
Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. [2005.08]
Evaluation of 2-column agglutination versus conventional tube technique for antibody screening. [2003.05]
Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. [2005.03]
Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura. [2005.03]
[The effect of opsonins on erythrocytes' phagocytosis in the vitreous--clinical observations (Part B)] [2004]
Prevention of immunization to D+ red blood cells with red blood cell exchange and intravenous Rh immune globulin. [2004.12]
Kleihauer-betke testing is important in all cases of maternal trauma. [2004.11]
Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. [2004.10]
The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative. [2004.09]
Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. [2004.07]
Isoimmunization in pregnancy. [2004.06]
Management of immune thrombocytopenic purpura in adults. [2004.04]
After eight-year-tolerance minimal i.v. anti-D infusions unleash hemolysis in a patient with immune thrombocytopenic purpura (ITP). [2004.04]
Postdelivery levels of anti-D IgG prophylaxis in D- mothers depend on maternal body weight. [2004.04]
Three cases of massive fetomaternal hemorrhage presenting without clinical suspicion. [2004.04]
Collaborative study for establishment of a global standard for the potency assay of human anti-D immunoglobulin. [2004.01]
Clinical features and treatment outcomes of 79 infants with immune thrombocytopenic purpura. [2004.01]
Use of intravenous anti-D in patients with refractory and relapsed immune thrombocytopenic purpura. [2003.11]
False positive Kleihauer tests and unnecessary administration of anti-D immunoglobulin. [2003.12]
Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. [2003.12]
A global standard for anti-D immunoglobulin: international collaborative study to evaluate a candidate preparation. [2003.11]
Rh negative status and isoimmunization update: a case-based approach to care. [2003.07]
Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. [2003.10.15]
Is the incidence of fetal-to-maternal hemorrhage increased in patients with third-trimester bleeding? [2003.06]
Prevalence of D(u) phenotype amongst rhesus negative females in Port Harcourt, Nigeria. [2003.04]
An audit of the investigation and use of anti-D immunoglobulin prophylaxis in Tayside. [2001.05]
Is Rh immune globulin needed in early first-trimester abortion? A review. [2003.03]
Lack of anti-D in women at birth following antepartum immune globulin prophylaxis. [2003.03.26]
Fetal-maternal hemorrhage detection in Ontario. [2003.01]
[Maternal complications of fetal hydrops] [2002.12.07]
Treatment requirements of infants with rhesus isoimmunisation within a geographically defined area. [2002.11]
Perinatal immunomodulation. [2002.05]
Incidence of Rhesus isoimmunization in Rhesus-negative mothers in Ramadi, Iraq, in the mid-1990s. [2000.09]
Anti-D exerts a very early response in childhood acute idiopathic thrombocytopenic purpura. [2002.09]
Idiopathic thrombocytopenic purpura diagnosed during the second decade of life. [2002.08]
[Foetal-maternal alloimmunizations in the South-East area of the Venice province] [2002.08]
Reported management of early-pregnancy bleeding and miscarriage by general practitioners in Victoria. [2002.01.21]
Intravenous anti-D immune globulin-induced intravascular hemolysis in Epstein-Barr virus-related thrombocytopenia. [2001.10]
Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. [2002.02]
Lack of association between hepatitis C viral RNA in serum and liver and histologic gradings: a study on Irish anti-D-treated patients. [2002.03]
Anti-D immunoglobulin treatment for thrombocytopenia associated with primary antibody deficiency. [2002.01]
[Immune cytopenias in newborns] [2001.09.15]
RhD isoimmunization and current management modalities. [2001.11]
Management of immune thrombocytopenic purpura in children. [2001.09]
Use of anti-D immunoglobulin in the treatment of threatened miscarriage in the accident and emergency department. [2001.11]
Intravenous Rh immune globulin for treating immune thrombocytopenic purpura. [2001.11]
Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content. [2001.06]
The frequency of anti-C + anti-G in the absence of anti-D in alloimmunized pregnancies. [2001.06]
Rhesus isoimmunization. [2001.05]
Detection of massive transplacental haemorrhage by flow cytometry. [2000.12]
The first example of a paraben-dependent antibody to an Rh protein. [2001.03]
Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis. [2001.01]
Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? [2000.12]
Pregnancy and pregnancy outcome in hepatitis C type 1b. [2000.09]
Policies and procedures related to weak D phenotype testing and Rh immune globulin administration. Results from supplementary questions to the Comprehensive Transfusion Medicine Survey of the College of American Pathologists. [2000.08]
Detection of multiple passively acquired alloantibodies following infusions of IV Rh immune globulin. [2000.05]
Anti-D administration after childbirth for preventing Rhesus alloimmunisation. [2000]
Anti-D administration in pregnancy for preventing rhesus alloimmunisation. [2000]
The fetal and neonatal outcomes of Rhesus D antibody affected pregnancies in Northern Ireland. [2000.01]
Evaluation of the safety of Rh immunoglobulin by monitoring viral markers among Rh-negative female blood donors. [2000]
The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin. [2000.03]
A likelihood-based method of identifying contaminated lots of blood product. [1999.08]
Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. [1999.05]
A second outbreak of hepatitis C virus infection from anti-D immunoglobulin in Ireland. [1999]
Transmission rates of hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation. [1999]
Evaluation by enzyme-linked immunosorbent assay of IgG anti-D and IgG subclass concentrations in immunoglobulin preparations. [1999.05]
Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. [1999.04.22]
Variation of hepatitis C virus following serial transmission: multiple mechanisms of diversification of the hypervariable region and evidence for convergent genome evolution. [1999.03]
Risk of hepatitis C infection in neonates transfused with blood from donors infected with hepatitis C. [1998.12]
The scientific basis of antenatal prophylaxis. [1998.11]
Use of Rh immune globulin: ASCP practice parameter. American Society of Clinical Pathologists. [1998.09]
|
